Soligenix announces partnership with sterling pharma solutions

U.s. expansion of synthetic hypericin active ingredient manufacturing princeton, n.j. , oct. 3, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has established a partnership agreement with sterling pharma solutions (sterling) to optimize and implement a commercially viable, scalable production technology for synthetic hypericin.
SNGX Ratings Summary
SNGX Quant Ranking